Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “VE303 is a live biotherapeutic product (LBP) consisting of 8 clonally derived, nonpathogenic, nontoxigenic, commensal bacteria strains manufactured under Good Manufacturing Practices (GMP) conditions.”In the company’s words, NCT06237452 on ClinicalTrials.gov
- Tested for
- Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, CDI, C. Diff Infection, Recurrent Clostridium Difficile Infection and 2 more
- Main trialPhase 3
- “The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).”In the company’s words, NCT06237452 on ClinicalTrials.gov
Other drugs for Clostridium Difficile
- DTpaGSK · Phase 3
- Investigational varicella vaccineGSK · Phase 3
- 13-Valent Pneumococcal Polysaccharide Conjugate VaccineCanSino Biologics Inc. · Phase 3
- Yellow fever vaccineSanofi · Phase 3
- Plasmodium immunotherapyCAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. · Phase 2/3
- Colgate SNaP Total 10/10Colgate Palmolive · Phase 3
Coming up1
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jun 2027 | VE303 for Prevention of Recurrent Clostridioides Difficile Infection | |
| Phase 2Completed | 2 Jun 2021 | Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026